Cerevel Therapeutics Holdings Inc. (CERE) Financial Statements (2024 and earlier)

Company Profile

Business Address 222 JACOBS STREET
CAMBRIDGE, MA 02141
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments990,965,000892,030,000565,688,000383,623,000
Cash and cash equivalents416,465,000136,521,000193,018,000383,623,000
Short-term investments574,500,000755,509,000372,670,000 
Receivables5,291,0002,046,000729,000 
Prepaid expense6,581,0006,016,0006,926,0004,955,000
Other current assets563,0001,459,000562,000160,000
Other undisclosed current assets3,538,0004,100,0004,112,0001,822,000
Total current assets:1,006,938,000905,651,000578,017,000390,560,000
Noncurrent Assets
Operating lease, right-of-use asset20,125,00021,820,00023,251,00024,459,000
Property, plant and equipment25,647,00027,467,00028,449,00024,165,000
Long-term investments and receivables185,199,00058,126,00052,269,000 
Long-term investments185,199,00058,126,00052,269,000 
Prepaid expense   1,806,0001,389,000
Restricted cash and investments1,960,0001,867,0004,200,0004,200,000
Other noncurrent assets3,429,0002,891,000  
Other undisclosed noncurrent assets   927,000500,000
Total noncurrent assets:236,360,000112,171,000110,902,00054,713,000
TOTAL ASSETS:1,243,298,0001,017,822,000688,919,000445,273,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities37,475,00035,658,00012,568,0006,143,000
Accounts payable11,863,00010,061,00011,298,0004,993,000
Accrued liabilities25,612,00025,597,0001,270,0001,150,000
Other undisclosed current liabilities54,704,00036,906,00029,970,00023,405,000
Total current liabilities:92,179,00072,564,00042,538,00029,548,000
Noncurrent Liabilities
Long-term debt and lease obligation337,424,000335,482,00034,110,00030,969,000
Long-term debt, excluding current maturities337,424,000335,482,000  
Liabilities, other than long-term debt27,786,00031,190,0002,000236,000
Other liabilities   2,000236,000
Operating lease, liability27,786,00031,190,00034,110,00030,969,000
Other undisclosed noncurrent liabilities112,164,00057,348,00033,540,000 
Total noncurrent liabilities:477,374,000424,020,00067,652,00031,205,000
Total liabilities:569,553,000496,584,000110,190,00060,753,000
Equity
Equity, attributable to parent673,745,000521,238,000578,729,000384,520,000
Common stock18,00016,00015,00013,000
Additional paid in capital2,072,553,0001,485,880,0001,195,944,000775,417,000
Accumulated other comprehensive income (loss)1,771,0003,097,000(986,000) 
Accumulated deficit(1,400,597,000)(967,755,000)(616,244,000)(390,910,000)
Total equity:673,745,000521,238,000578,729,000384,520,000
TOTAL LIABILITIES AND EQUITY:1,243,298,0001,017,822,000688,919,000445,273,000

Income Statement (P&L) (USD)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating expenses(447,265,000)(367,848,000)(220,098,000)(149,116,000)
Operating loss:(447,265,000)(367,848,000)(220,098,000)(149,116,000)
Nonoperating income (expense)25,493,0006,878,000(5,393,000)(3,274,000)
Investment income, nonoperating43,865,000   
Other nonoperating income (expense)(18,372,000)6,878,000(5,393,000)(3,274,000)
Interest and debt expense(10,567,000)(3,918,000)  
Loss from continuing operations before equity method investments, income taxes:(432,339,000)(364,888,000)(225,491,000)(152,390,000)
Other undisclosed income from continuing operations before income taxes  13,537,000157,000224,000
Loss from continuing operations before income taxes:(432,339,000)(351,351,000)(225,334,000)(152,166,000)
Income tax expense (benefit)(503,000)(160,000) 24,000
Loss from continuing operations:(432,842,000)(351,511,000)(225,334,000)(152,142,000)
Loss before gain (loss) on sale of properties:(225,334,000)(152,142,000)
Net loss attributable to parent:(432,842,000)(351,511,000)(225,334,000)(152,142,000)
Other undisclosed net income available to common stockholders, basic    3,871,000
Net loss available to common stockholders, diluted:(432,842,000)(351,511,000)(225,334,000)(148,271,000)

Comprehensive Income (USD)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net loss:(432,842,000)(351,511,000)(225,334,000)(152,142,000)
Other comprehensive income (loss)(1,326,000)4,083,000(986,000) 
Comprehensive loss, net of tax, attributable to parent:(434,168,000)(347,428,000)(226,320,000)(152,142,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: